CTOs on the Move

Concerro

www.concerro.com

 
Concerro is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.concerro.com
  • 9276 Scranton Rd Ste 400
    San Diego, CA USA 92121
  • Phone: 858.882.8500

Executives

Name Title Contact Details

Similar Companies

Achaogen

Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat multi-drug resistant, or MDR, gram-negative infections. We are anchored in our work by our key values of integrity, accountability, transparency, scientific rigor and drive. We pride ourselves in creating a work community that is patient-centric, scientifically driven, supportive, and collaborative, and that encourages the diversity of thought leading to great innovation. We are always excited to add people to our dynamic team who thrive in our community and who are driven and motivated to transform the lives of patients.

Ziemer USA INC

Ziemer USA INC is a Wood River, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cullinan Oncology

Cullinan Oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. Sourced from the Cullinan dry lab as well as external collaborators, Cullinan`s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.

Reflex Photonics

Reflex Photonics Inc. is a Sherbrooke, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Exonics Therapeutics

Exonics Therapeutics was launched in February 2017 to advance the research of our scientific founder, Dr. Eric Olson and his laboratory at the University of Texas Southwestern Medical Center (UTSW) to develop treatments for patients with neuromuscular diseases. Dr. Olson is one of the world’s leading experts in the study of muscle cells and the application of gene editing to treat these types of diseases. In particular, Dr. Olson’s laboratory has used adeno-associated virus (AAV) to deliver a CRISPR/Cas9 technology that can identify and repair exon mutations to restore the production of dystrophin, a protein that helps stabilize and protect muscle fibers. Dystrophin is the protein missing in boys with Duchenne. The loss of dystrophin causes Duchenne.